Detalhe da pesquisa
1.
A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.
Br J Clin Pharmacol
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38830622
2.
Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects.
Drug Metab Dispos
; 51(8): 995-1004, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407094
3.
Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Drug Metab Dispos
; 51(4): 451-463, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36639243
4.
Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity.
Br J Clin Pharmacol
; 88(9): 4121-4133, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404513
5.
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Br J Clin Pharmacol
; 85(4): 762-770, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30618054
6.
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
Int J Clin Pharmacol Ther
; 50(11): 765-77, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22943931
7.
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
Drugs R D
; 22(1): 35-42, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133636
8.
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Clin Drug Investig
; 41(10): 895-905, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34546534
9.
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Clin Transl Sci
; 14(3): 812-819, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32770730
10.
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.
Clin Pharmacol Drug Dev
; 9(3): 411-421, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31793171
11.
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
Clin Transl Sci
; 13(2): 275-283, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31584739
12.
Incurred sample reanalysis in AstraZeneca small molecule portfolio - what have we learned and where do we go next?
Bioanalysis
; 10(21): 1733-1745, 2018 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30325197
13.
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Clin Transl Sci
; 11(3): 330-338, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29517132
14.
Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).
BMJ Open
; 8(5): e021878, 2018 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29844102
15.
The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
Diabetes Res Clin Pract
; 98(3): 436-44, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23010558